Morgan Stanley analyst Michael Ulz upgrades Vir Biotechnology (NASDAQ:VIR) from Underweight to Equal-Weight and raises the price target from $18 to $30.
Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather disappointing."
The European average rate of receiving booster doses was only 29% in the groups considered to be at the highest risk.